Actuate Therapeutics, Inc. (ACTU)

NASDAQ: ACTU · Real-Time Price · USD

1.270

+0.040 (3.25%)

At close: Aug 21, 2026, 4:00 PM EDT

1.290

+0.020 (1.57%)

After-hours: Aug 21, 2026, 7:30 PM EDT

Actuate Therapeutics Earnings Call Transcripts

Fiscal Year 2025

Study update
A large phase II randomized trial of elraglusib in first-line metastatic pancreatic cancer showed a significant and durable overall survival benefit, with a favorable safety profile and improved quality of life. The drug's unique mechanism and combinability position it as a promising new platform for pancreatic and other GI cancers.

Read full transcript →

Press release